Monthly M&A Insider - Mergermarket
Monthly M&A Insider - Mergermarket
Monthly M&A Insider - Mergermarket
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Germany<br />
Consolidating the German newspaper industry<br />
• Germany’s newspaper industry is highly fragmented and<br />
has always been a likely area for consolidations. The most<br />
controversial consolidation in the German newspaper<br />
market was the acquisition of BV Deutsche Zeitungsholding<br />
by Mecom in 2007.<br />
• In the last few years however, the inability of newspapers<br />
to become profitable online and declining circulation has led<br />
to lower advertising, copy sales, and subscription revenue.<br />
Particularly the decline in advertising revenue has been<br />
exacerbated by the current economic downturn. This,<br />
coupled with the high and inflexible fixed costs newspaper<br />
publishing incurs, has proved a strong incentive for<br />
consolidations, as the industry looks to achieve economies<br />
of scope and scale.<br />
• As one would expect in an industry sensitive to swings in<br />
the economy, the German newspaper industry has shown<br />
increased activity over the past month, with Mecom<br />
selling it’s German operations, including “Berliner Kurier”,<br />
“Berliner Zeitung”, “TIP Verlag GmbH”, and “Hamburger<br />
Morgenpost”, to the German publisher M. DuMont<br />
Schauberg (MDS) for €152m, making MDS Germany’s third<br />
largest newspaper publisher. MDS subsequently<br />
sold a 35% stake of this on to Heinen Verlag, another<br />
German publisher.<br />
• Verlagsgruppe Georg von Holtzbrinck sold the<br />
Verlagsgruppe Handelsblatt (VHB), including<br />
“Handelsblatt”, “Wirtschaftswoche” and “Tagesspiegel”,<br />
and a 50% stake in “Die Zeit” to Dieter von Holtzbrinck<br />
Medien GmbH. Additionally, Stefan von Holtzbrinck,<br />
chairman of the Verlagsgruppe Georg von Holtzbrinck<br />
Verlag is interested in making acquisitions among regional<br />
newspapers and said the company will keep its eyes open.<br />
• Is this trend set to continue? Axel Springer, the listed<br />
German publisher, certainly thinks so. The publisher would<br />
also be interested in buying German regional newspapers<br />
according to chief executive Matthias Doepfner, citing the<br />
global financial crisis as providing good opportunities for<br />
acquisitions in both print and online media.<br />
• Another possible deal looming in the near future could be<br />
the acquisition of Schleswig-Holsteinischer Zeitungsverlag<br />
(SHZ). According to the Financial Times Deutschland, SHZ<br />
is seeking a buyer for itself, in a deal expected to be worth<br />
€ 400m with the rival German publisher Madsack thought<br />
to be a likely buyer.<br />
• Furthermore, smaller family-owned newspaper groups<br />
might come on to the market as they lack successors and<br />
funds for both the expansion into the digital arena and to<br />
survive the economic downturn.<br />
Novartis: Alcon commitment prioritised over<br />
move for Bayer, insider says<br />
• Novartis does not envisage “mega-deals” such as the<br />
acquisition of Bayer, said a Novartis insider. The insider said<br />
Novartis is already well-diversified and also mentioned the<br />
commitment of the Swiss listed pharma company to the<br />
acquisition of Alcon, for which it still has to make another<br />
payment of some $28bn.<br />
• This month, Novartis was rumoured it may offer €42.55<br />
per share for Bayer, the listed German chemicals/<br />
pharmaceuticals company, although no company<br />
spokesperson could confirm or deny the rumours.<br />
• Sector analysts further believe that Novartis could be<br />
planning a move for Austrian vaccines developer Intercell<br />
in due course. The two firms are already involved in a<br />
partnership and a takeover by Novartis was described as<br />
an obvious move. When asked, an Intercell source did not<br />
deny Novartis could be interested in such a move.<br />
• Last month, a Novartis spokesperson had told this news<br />
service that bolt-ons in the range of some CHF 100m<br />
(€66m) are part of the Swiss pharma company’s strategy.<br />
A large acquisition is unlikely to take place in the near<br />
future, the spokesperson added at the time, with reference<br />
to a statement by Novartis’ CEO Daniel Vasella.<br />
<strong>Monthly</strong> M&A report – 111